Immune Checkpoint Inhibitor-Induced Myocarditis in a Patient with Metastatic Melanoma: A Case Report
Year: 2025
Type: article
Abstract: Background: Immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1 and PD-L1 have transformed treatment of metastaticmelanoma and other cancers, but the same mechanism that unleashes anti-tumour immunity can also attack the myocardium.Objective: To review the published case reports, series, registries and mechanistic literature on ICI myocarditis, drawing onmelanoma-specific reports where the literature specifies them.Methods: Narrative review of case reports, case series, pharmacovigilance analyses, registry cohorts, mechanistic studies andguideline documents.Findings: Reported incidence ranges from roughly 0.06% to 1.3% of ICI-treated patients, rising toward 2% with combinationtherapy. Onset is typically early (median 34 days, one registry of 35 patients), and historical fatality has reached 25-50%.Published cases document fulminant presentations with conduction abnormalities, cardiogenic shock and myositis; refractorycases have been treated with anti-thymocyte globulin, abatacept and ruxolitinib, the latter combination linked in one cohort to amarked fatality reduction.Conclusions: The published record supports early biomarker-based suspicion, prompt ICI discontinuation, and stepwiseescalation of immunosuppression in refractory disease, with still-limited evidence for targeted second-line agents
Authors: Fitzgerald C, Lombardi C, Boer JD
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7208813890
